Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Label Single Arm Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Next Previous
Search
Trial Profile

A Multicenter, Open Label Single Arm Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Disitamab vedotin (Primary)
  • Indications Bladder cancer; Renal cancer; Ureteral neoplasms; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors RemeGen

    • Most Recent Events

    • 08 Jan 2025 According to RemeGen media release, based on the results of this study Disitamab-vedotin has been approved in China for patients with HER2-overexpressing la/mUC previously treated with platinum-containing chemotherapy.
    • 10 Apr 2024 Pooled analysis results presented at the 115th Annual Meeting of the American Association for Cancer Research
    • 12 Nov 2023 Results of data analyzed and reported are from RC48-C005 and RC48-C009 trials assessing the efficacy and safety of disitamab vedotin (DV, RC48-ADC), a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E, in patients with HER2-positive locally advanced or metastatic urothelial carcinoma (UC) refractory to standard or regular therapies, published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top